The Common Alzheimer's Disease Research Ontology (CADRO) for biomarker categorization.

ABSTRACT: Biomarkers are vital to Alzheimer's disease (AD) drug development and clinical trials, and will have an increasing role in clinical care. In this narrative review, we demonstrate the use of the National Institutes on Aging/Alzheimer's Association (NIA/AA) Common Alzheimer's Disease Research Ontology (CADRO) system for the categorization of biomarkers based on the primary mechanism on which they report. We show that biomarkers are available (in various levels of validation) for all CADRO processes. Application of the CADRO system demonstrates gaps in the field where novel biomarkers are needed for specific aspects of the disease, and assays to detect and measure biological changes, in individuals with symptomatic or preclinical AD. We demonstrate the CADRO system as a means of categorizing

SUBMITTER: Leisgang Osse AM 

PROVIDER: S-EPMC11812129 | biostudies-literature | 2025 Jan-Mar

REPOSITORIES: biostudies-literature